Table 3.
Antibody profile in celiac disease patients and non-celiac disease controls
| Anti-tTG-IgA | Anti-tTG-IgG | Anti-DGP-IgA | Anti-DGP-IgG | CD patients n = 50 | Non-CD controls n = 50 | Total n = 100 | Classification in combination (anti-tTG-IgA/IgG + anti-DGP-IgG/IgA) |
| + | + | + | + | 7 (14%) | 0 | 7 | 49 positives |
| + | + | - | + | 11 (22%) | 0 | 11 | |
| + | - | + | + | 8 (16%) | 0 | 8 | |
| + | - | - | + | 17 (34%) | 0 | 17 | |
| - | + | - | + | 61 (12%) | 0 | 6 | |
| - | - | - | + | 1 (2%) | 2 (4%) | 3 | 5 not classified |
| - | - | + | - | 0 | 1 (2%) | 1 | |
| - | + | - | - | 0 | 1 (2%) | 1 | |
| - | - | - | - | 0 | 46 (92%) | 46 | 46 negatives |
Patients with confirmed selective IgA deficiency. +: Antibody present; -: Antibody absent; Using the combination of four antibodies (anti-tTG-IgA/IgG + anti-DGP-IgG/IgA) classified 49 children as CD positive, 46 as CD negative, and 5 were neither classified as CD positive nor negative with further verification needed. CD: Celiac disease; DGP: Deamidated gliadin peptides; tTG: Tissue transglutaminase.